Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141(+) dendritic cells to activate naïve and memory WT1‐specific CD8(+) T cells

OBJECTIVES: Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8(+) T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141(+) dendritic cells (DCs). The C‐type lectin‐like receptor CLEC9A is expressed exclus...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearson, Frances E, Tullett, Kirsteen M, Leal‐Rojas, Ingrid M, Haigh, Oscar L, Masterman, Kelly‐Anne, Walpole, Carina, Bridgeman, John S, McLaren, James E, Ladell, Kristin, Miners, Kelly, Llewellyn‐Lacey, Sian, Price, David A, Tunger, Antje, Schmitz, Marc, Miles, John J, Lahoud, Mireille H, Radford, Kristen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292901/
https://www.ncbi.nlm.nih.gov/pubmed/32547743
http://dx.doi.org/10.1002/cti2.1141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292901/
https://www.ncbi.nlm.nih.gov/pubmed/32547743
http://dx.doi.org/10.1002/cti2.1141

Ejemplares similares